Montreal-based Theratechnologies Inc. is planning a FDA submission shortly, after a three-month delay, for its novel therapy for multi-drug resistant HIV, ibalizumab. Analysts are confident of its quick success at the agency, given the novel product's efficacy and the unmet patient need, which should propel the company to a different league, sales-wise. HIV may have morphed into a long-term illness with the arrival of highly active antiretroviral therapy, but more and more patients are now running through the current treatment options, increasing the demand for novel treatment strategies.
There are about one million HIV patients in the US, of whom between 43% and 63% are on antiretroviral therapy,...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)